Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis

[1]  L. Zitvogel,et al.  Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers , 2021, Cell Death & Disease.

[2]  M. M. van der Eerden,et al.  Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19) , 2021, Nature communications.

[3]  K. Chow,et al.  Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19 , 2021, Gut.

[4]  O. Schwartz,et al.  IgA dominates the early neutralizing antibody response to SARS-CoV-2 , 2020, Science Translational Medicine.

[5]  A. D. Salman.  COVID-19 PATIENTS , 2021 .

[6]  P. Klenerman,et al.  Autophagy in T cells from aged donors is maintained by spermidine and correlates with function and vaccine responses , 2020, eLife.

[7]  Praveen Reddy Moole,et al.  Effect of Deoxycholic Acid on Immune Cells - An Immunophenotyping Analysis of Peripheral Blood and Splenic Lymphocytes in CD57 Female Mice , 2020, International Journal of Pharmaceutical Investigation.

[8]  N. E. Babady,et al.  Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer , 2020, The New England journal of medicine.

[9]  Gaurav D. Gaiha,et al.  Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host , 2020, The New England journal of medicine.

[10]  E. Fischer,et al.  Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer , 2020, Cell.

[11]  L. Zitvogel,et al.  The immuno-oncological challenge of COVID-19 , 2020, Nature Cancer.

[12]  D. Raoult,et al.  Correlation between 3790 qPCR positives samples and positive cell cultures including 1941 SARS-CoV-2 isolates , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  N. Chaput,et al.  Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort , 2020, Nature Cancer.

[14]  M. Loda,et al.  SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19 , 2020, Cancer Cell.

[15]  W. Guan,et al.  Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial. , 2020, JAMA internal medicine.

[16]  P. Kelly,et al.  Immune profiling of COVID-19 patients , 2020 .

[17]  F. Coutlée,et al.  Comparison of SARS-CoV-2 detection from combined nasopharyngeal/oropharyngeal swab samples by a laboratory-developed real-time RT-PCR test and the Roche SARS-CoV-2 assay on a cobas 8800 instrument , 2020, Journal of Clinical Virology.

[18]  W. Miller,et al.  High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort study , 2020, European Journal of Cancer.

[19]  E. Sklan,et al.  Nasopharyngeal viral load predicts hypoxemia and disease outcome in admitted COVID-19 patients , 2020, Critical Care.

[20]  S. Farhadian,et al.  Sex differences in immune responses that underlie COVID-19 disease outcomes , 2020, Nature.

[21]  N. Babel,et al.  Impaired Cytotoxic CD8+ T Cell Response in Elderly COVID-19 Patients , 2020, mBio.

[22]  Kelsey K. Finn,et al.  Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19 , 2020, Cell.

[23]  J. Mason,et al.  A dynamic COVID-19 immune signature includes associations with poor prognosis , 2020, Nature Medicine.

[24]  G. Corrao,et al.  Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study , 2020, The Lancet Haematology.

[25]  Madeleine K. D. Scott,et al.  Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans , 2020, Science.

[26]  I. Amit,et al.  Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19 , 2020, Cell.

[27]  M. Rugge,et al.  SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer , 2020, Nature Cancer.

[28]  Siyuan Li,et al.  Infection of human lymphomononuclear cells by SARS-CoV-2 , 2020, bioRxiv : the preprint server for biology.

[29]  F. Vély,et al.  Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis , 2020, Nature.

[30]  O. Kirk,et al.  Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy , 2020, The Journal of infectious diseases.

[31]  M. Chua,et al.  Clinical outcomes of coronavirus disease 2019 (COVID‐19) in cancer patients with prior exposure to immune checkpoint inhibitors , 2020, Cancer communications.

[32]  R. Hotchkiss,et al.  Association of Interleukin 7 Immunotherapy With Lymphocyte Counts Among Patients With Severe Coronavirus Disease 2019 (COVID-19) , 2020, JAMA network open.

[33]  Roland Eils,et al.  COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis , 2020, Nature Biotechnology.

[34]  D. Raoult,et al.  Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis , 2020, Travel Medicine and Infectious Disease.

[35]  E. Robilotti,et al.  Determinants of COVID-19 disease severity in patients with cancer , 2020, Nature Medicine.

[36]  A. Drilon,et al.  COVID-19 in patients with lung cancer , 2020, Annals of Oncology.

[37]  V. Torri,et al.  COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study , 2020, The Lancet Oncology.

[38]  S. Farhadian,et al.  Sex differences in immune responses to SARS-CoV-2 that underlie disease outcomes , 2020, medRxiv.

[39]  M. M. van der Eerden,et al.  Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants , 2020, medRxiv.

[40]  H. Su,et al.  [Pathological changes of the spleen in ten patients with coronavirus disease 2019(COVID-19) by postmortem needle autopsy]. , 2020 .

[41]  J. Blay,et al.  High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR , 2020, European Journal of Cancer.

[42]  P. Klenerman,et al.  Autophagy in T cells from aged donors is maintained by spermidine, and correlates with function and vaccine responses , 2020, bioRxiv.

[43]  Sasikanth Manne,et al.  Deep immune profiling of COVID-19 patients reveals patient heterogeneity and distinct immunotypes with implications for therapeutic interventions , 2020, bioRxiv.

[44]  M. Trauner,et al.  Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome: Results From a Prospective, Single-Center, Clinicopathologic Case Series , 2020, Annals of Internal Medicine.

[45]  M. Piris,et al.  Survival study of hospitalised patients with concurrent COVID‐19 and haematological malignancies , 2020, British journal of haematology.

[46]  G. Ottaviani,et al.  The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): Report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities , 2020, Cardiovascular Pathology.

[47]  M. Santillana,et al.  Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak , 2020, Cancer discovery.

[48]  L. Malle.  A map of SARS-CoV-2 and host cell interactions , 2020, Nature Reviews Immunology.

[49]  Matthew D. Park,et al.  Macrophages: a Trojan horse in COVID-19? , 2020, Nature Reviews Immunology.

[50]  Peter T. McKenney,et al.  Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells , 2020, Nature.

[51]  Qiongjing Yuan,et al.  The epidemiology and clinical information about COVID-19 , 2020, European Journal of Clinical Microbiology & Infectious Diseases.

[52]  P. Vollmar,et al.  Virological assessment of hospitalized patients with COVID-2019 , 2020, Nature.

[53]  Philippe Brouqui,et al.  Rapid viral diagnosis and ambulatory management of suspected COVID-19 cases presenting at the infectious diseases referral hospital in Marseille, France, - January 31st to March 1st, 2020: A respiratory virus snapshot , 2020, Travel Medicine and Infectious Disease.

[54]  Fabian J Theis,et al.  SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues , 2020, Cell.

[55]  M. Surette,et al.  Type 2 diabetes influences bacterial tissue compartmentalisation in human obesity , 2020, Nature Metabolism.

[56]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[57]  Victor M Corman,et al.  Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[58]  M. Arumugam,et al.  Trust is good, control is better: technical considerations in blood microbiome analysis , 2019, Gut.

[59]  C. Benoist,et al.  Microbial bile acid metabolites modulate gut RORγ+ regulatory T cell homeostasis , 2019, Nature.

[60]  A. Ballabio,et al.  Polyamines Control eIF5A Hypusination, TFEB Translation, and Autophagy to Reverse B Cell Senescence , 2019, Molecular cell.

[61]  A. Freifeld,et al.  Epidemiology, Diagnosis, Treatment, and Prevention of Influenza Infection in Oncology Patients. , 2019, Journal of oncology practice.

[62]  Lai Guan Ng,et al.  Dimensionality reduction for visualizing single-cell data using UMAP , 2018, Nature Biotechnology.

[63]  R. Hotchkiss,et al.  Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. , 2018, JCI insight.

[64]  Mahendra Mariadassou,et al.  FROGS: Find, Rapidly, OTUs with Galaxy Solution , 2018, Bioinform..

[65]  L. Leibovici,et al.  Influenza vaccines in immunosuppressed adults with cancer. , 2018, The Cochrane database of systematic reviews.

[66]  S. Mangul.  Microbiome Analysis , 2018, Methods in Molecular Biology.

[67]  K. Kalanetra,et al.  Hepatic inflammation caused by dysregulated bile acid synthesis is reversible by butyrate supplementation , 2017, The Journal of pathology.

[68]  R. Halaban,et al.  Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[69]  S. Perlman,et al.  Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology , 2017, Seminars in Immunopathology.

[70]  F. Servant,et al.  Comprehensive description of blood microbiome from healthy donors assessed by 16S targeted metagenomic sequencing , 2016, Transfusion.

[71]  P. Schnitzler,et al.  Long-Term Shedding of Influenza Virus, Parainfluenza Virus, Respiratory Syncytial Virus and Nosocomial Epidemiology in Patients with Hematological Disorders , 2016, PloS one.

[72]  F. Servant,et al.  The Characterization of Novel Tissue Microbiota Using an Optimized 16S Metagenomic Sequencing Pipeline , 2015, PloS one.

[73]  P. Klenerman,et al.  Autophagy is a critical regulator of memory CD8+ T cell formation , 2014, eLife.

[74]  P. Song,et al.  CLINICAL OUTCOMES? , 2014 .

[75]  U. Buchholz,et al.  Risk factors and containment of respiratory syncytial virus outbreak in a hematology and transplant unit , 2013, Bone Marrow Transplantation.

[76]  J. Blay,et al.  CD4 lymphopenia to identify end-of-life metastatic cancer patients. , 2013, European journal of cancer.

[77]  U. Buchholz,et al.  Molecular Characterization of a Respiratory Syncytial Virus Outbreak in a Hematology Unit in Heidelberg, Germany , 2012, Journal of Clinical Microbiology.

[78]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[79]  M. Boeckh,et al.  Human rhinovirus and coronavirus detection among allogeneic hematopoietic stem cell transplantation recipients. , 2010, Blood.

[80]  Gregor Rothe,et al.  Inhibitory effect of tumor cell-derived lactic acid on human T cells. , 2007, Blood.

[81]  C. Rose,et al.  Institut National de la Santé et de la Recherche Médicale , 1976 .

[82]  B. Hagberg,et al.  CLINICAL CHARACTERISTICS , 1972 .

[83]  E. Glaser.  The randomized clinical trial. , 1972, The New England journal of medicine.

[84]  The Inhibitory Effect , 2022 .